These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 2648143

  • 1. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.
    Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J.
    N Engl J Med; 1989 Mar 30; 320(13):828-34. PubMed ID: 2648143
    [Abstract] [Full Text] [Related]

  • 2. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 30; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 3. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, O'Donnell M, Smith EP, Stepan DE, Molina A.
    Blood; 1995 Aug 01; 86(3):1228-34. PubMed ID: 7620176
    [Abstract] [Full Text] [Related]

  • 4. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D, Schwaighofer H, Thaler J, Weyrer W, Fink M, Nussbaumer W, Fritsch E, Niederwieser D.
    Wien Klin Wochenschr; 1994 Aug 01; 106(7):201-7. PubMed ID: 8197754
    [Abstract] [Full Text] [Related]

  • 5. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.
    Wawer A, Laws HJ, Dilloo D, Göbel U, Burdach S.
    Klin Padiatr; 2004 Aug 01; 216(3):169-75. PubMed ID: 15175962
    [Abstract] [Full Text] [Related]

  • 6. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
    Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I.
    J Clin Oncol; 1994 Sep 01; 12(9):1923-30. PubMed ID: 8083714
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM.
    N Engl J Med; 1993 Oct 21; 329(17):1225-30. PubMed ID: 8413388
    [Abstract] [Full Text] [Related]

  • 8. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec 21; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 21; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
    Wagner JE, Thompson JS, Carter SL, Kernan NA, Unrelated Donor Marrow Transplantation Trial.
    Lancet; 1997 Apr 21; 366(9487):733-41. PubMed ID: 16125590
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S.
    Haematologica; 1998 Jan 21; 83(1):48-55. PubMed ID: 9542323
    [Abstract] [Full Text] [Related]

  • 16. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran.
    Alimoghaddam K, Ghaffari H, Foroughi F, Chardouli B, Sanaat Z, Bahar B, Mousavi A, Iravani M, Ghavamzadeh A.
    Arch Iran Med; 2006 Apr 21; 9(2):99-103. PubMed ID: 16649348
    [Abstract] [Full Text] [Related]

  • 17. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V.
    N Engl J Med; 1986 Mar 20; 314(12):729-35. PubMed ID: 3513012
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.